Portal de Periódicos da CAPES

Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy

2020; Mary Ann Liebert, Inc.; Volume: 31; Issue: 13-14 Linguagem: Inglês

10.1089/hum.2020.182

1557-7422

James M. Wilson, Terence R. Flotte,

Cellular transport and secretion

Human Gene TherapyVol. 31, No. 13-14 EditorialMoving Forward After Two Deaths in a Gene Therapy Trial of Myotubular MyopathyJames M. Wilson and Terence R. FlotteJames M. WilsonGene Therapy Program, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.Search for more papers by this author and Terence R. FlotteEditor-in-Chief, Human Gene Therapy, University of Massachusetts Medical School, Worcester, Massachusetts, USA.Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA.Search for more papers by this authorPublished Online:15 Jul 2020https://doi.org/10.1089/hum.2020.182AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy." Human Gene Therapy, 31(13-14), pp. 695–696FiguresReferencesRelatedDetailsCited byImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer2 March 2023 | BioDrugs, Vol. 33Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrierMolecular Therapy, Vol. 31, No. 3Immune responses in the mammalian inner ear and their implications for AAV-mediated inner ear gene therapyHearing Research, Vol. 116Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno‐associated viral vectors14 February 2023 | Medicinal Research Reviews, Vol. 539Neonatal Fc receptor inhibition enables adeno-associated virus gene therapy despite pre-existing humoral immunity Makoto Horiuchi, Christian J. Hinderer, Hailey N. Shankle, Peter M. Hayashi, Jessica A. Chichester, Casey Kissel, Peter Bell, Cecilia Dyer, and James M. Wilson31 January 2023 | Human Gene Therapy, Vol. 0, No. jaClinical trials and promising preclinical applications of CRISPR/Cas gene editingLife Sciences, Vol. 312The First Three Decades of Gene TherapyThe American Biology Teacher, Vol. 85, No. 1Food and Drug Administration Guidance on Design of Clinical Trials for Gene Therapy Products with Potential for Genome Integration or Genome Editing and Associated Long-Term Follow-Up of Research Subjects Daniel Eisenman and Scott Swindle23 November 2022 | Applied Biosafety, Vol. 27, No. 4Intrabiliary infusion of naked DNA vectors targets periportal hepatocytes in miceMolecular Therapy - Methods & Clinical Development, Vol. 27Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing10 October 2022 | Nature Communications, Vol. 13, No. 1In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations27 November 2022 | Genes, Vol. 13, No. 12Evading and overcoming AAV neutralization in gene therapyTrends in Biotechnology, Vol. 21Strategies for Bottlenecks of rAAV-Mediated Expression in Skeletal and Cardiac Muscle of Duchenne Muscular Dystrophy3 November 2022 | Genes, Vol. 13, No. 11Advances in CRISPR Delivery Methods: Perspectives and Challenges Selami Demirci, Khaled Essawi, Paula Germino-Watnick, Xiong Liu, Waleed Hakami, and John F. Tisdale13 October 2022 | The CRISPR Journal, Vol. 5, No. 5Cryo-electron Microscopy of Adeno-associated Virus16 May 2022 | Chemical Reviews, Vol. 122, No. 17Onasemnogene abeparvovec for the treatment of spinal muscular atrophy2 May 2022 | Expert Opinion on Biological Therapy, Vol. 22, No. 9Insight and Development of Advanced Recombinant Adeno-Associated Virus Analysis Tools Exploiting Single-Particle Quantification by Multidimensional Droplet Digital PCR Jeanette Zanker, Sara Lázaro-Petri, Daniela Hüser, Regine Heilbronn, and Adrien Savy16 September 2022 | Human Gene Therapy, Vol. 33, No. 17-18Adeno-associated virus mediates gene transduction after static cold storage treatment in rodent lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, Vol. 14Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models6 October 2021 | Gene Therapy, Vol. 29, No. 9Gene Electrotransfer into Mammalian Cells Using Commercial Cell Culture Inserts with Porous Substrate16 September 2022 | Pharmaceutics, Vol. 14, No. 9Adeno-Associated Virus Receptor-Binding: Flexible Domains and Alternative Conformations through Cryo-Electron Tomography of Adeno-Associated Virus 2 (AAV2) and AAV5 ComplexesJournal of Virology, Vol. 96, No. 13Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disordersMolecular Therapy, Vol. 30, No. 7Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platformsMolecular Therapy, Vol. 30, No. 7Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin geneMolecular Therapy, Vol. 30, No. 7Fantastic AAV Gene Therapy Vectors and How to Find Them—Random Diversification, Rational Design and Machine Learning3 July 2022 | Pathogens, Vol. 11, No. 7Cas-Based Systems for RNA Editing in Gene Therapy of Monogenic Diseases: In Vitro and in Vivo Application and Translational Potential16 June 2022 | Frontiers in Cell and Developmental Biology, Vol. 10CRISPR Modeling and Correction of Cardiovascular DiseaseCirculation Research, Vol. 130, No. 12Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector Han Zhang, Nathan Bamidele, Pengpeng Liu, Ogooluwa Ojelabi, Xin D. Gao, Tomás Rodriguez, Haoyang Cheng, Karen Kelly, Jonathan K. Watts, Jun Xie, Guangping Gao, Scot A. Wolfe, Wen Xue, and Erik J. Sontheimer14 June 2022 | GEN Biotechnology, Vol. 1, No. 3Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease4 June 2022 | Cells, Vol. 11, No. 11Efficacy and Safety of a Krabbe Disease Gene Therapy Juliette Hordeaux, Brianne A. Jeffrey, Jinlong Jian, Gourav R. Choudhury, Kristofer Michalson, Thomas W. Mitchell, Elizabeth L. Buza, Jessica Chichester, Cecilia Dyer, Jessica Bagel, Charles H. Vite, Allison M. Bradbury, and James M. Wilson16 May 2022 | Human Gene Therapy, Vol. 33, No. 9-10Endobronchial Aerosolized AAV1.SERCA2a Gene Therapy in a Pulmonary Hypertension Pig Model: Addressing the Lung Delivery Bottleneck Olympia Bikou, Serena Tharakan, Kelly P. Yamada, Taro Kariya, Jaume Aguero, Alexandra Gordon, Renata Mazurek, Tadao Aikawa, Erik Kohlbrenner, Kenneth M. Fish, Roger J. Hajjar, and Kiyotake Ishikawa16 May 2022 | Human Gene Therapy, Vol. 33, No. 9-10Adeno-associated virus (AAV) cell entry: structural insightsTrends in Microbiology, Vol. 30, No. 5Gene therapy for neuromuscular disorders: prospects and ethics30 August 2021 | Archives of Disease in Childhood, Vol. 107, No. 5Gene therapy in neuromuscular disorders1 May 2022 | Arquivos de Neuro-Psiquiatria, Vol. 80, No. 5 suppl 1Genetic therapies for neurological disorders22 November 2021 | Human Genetics, Vol. 141, No. 5The Diversity of Parvovirus Telomeres27 April 2022Revisiting the role of pulsed electric fields in overcoming the barriers to in vivo gene electrotransferBioelectrochemistry, Vol. 144Leveraging rAAV bioprocess understanding and next generation bioanalytics developmentCurrent Opinion in Biotechnology, Vol. 74Durability of transgene expression after rAAV gene therapyMolecular Therapy, Vol. 30, No. 4Electroporation and Electrochemotherapy in Gynecological and Breast Cancer Treatment12 April 2022 | Molecules, Vol. 27, No. 8Bioinks and Bioprinting Strategies for Skeletal Muscle Tissue Engineering3 February 2022 | Advanced Materials, Vol. 34, No. 12Nonhuman Primates in Translational ResearchAnnual Review of Animal Biosciences, Vol. 10, No. 1Gene therapy and gene correction: targets, progress, and challenges for treating human diseases9 October 2020 | Gene Therapy, Vol. 29, No. 1-2Advances in Ophthalmic Optogenetics: Approaches and Applications8 February 2022 | Biomolecules, Vol. 12, No. 2In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges18 January 2022 | Frontiers in Medicine, Vol. 8Poly(disulfide)s: From Synthesis to Drug Delivery7 December 2021 | Biomacromolecules, Vol. 23, No. 1Current and future treatment approaches for Barth syndrome10 November 2021 | Journal of Inherited Metabolic Disease, Vol. 45, No. 1Targeted Therapeutics for Rare DisordersNon-invasive gene delivery across the blood-brain barrier: present and future perspectivesNeural Regeneration Research, Vol. 17, No. 4Condon Optimization: Codon Optimization of Therapeutic Proteins: Suggested Criteria for Increased Efficacy and Safety9 August 2022Advanced therapeutic strategy for hereditary neuromuscular diseasesMolecular Therapy, Vol. 30, No. 1Updates on Cardiac Gene Therapy Research and Methods: Overview of Cardiac Gene Therapy31 August 2022Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeysMolecular Therapy - Methods & Clinical Development, Vol. 23Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous virusesMolecular Therapy, Vol. 29, No. 12Viral vector platforms within the gene therapy landscape8 February 2021 | Signal Transduction and Targeted Therapy, Vol. 6, No. 1Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions3 March 2021 | Gene Therapy, Vol. 28, No. 12Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo1 November 2021 | Nature Communications, Vol. 12, No. 1Assessment of quality attributes for adeno‐associated viral vectors5 August 2021 | Biotechnology and Bioengineering, Vol. 118, No. 11The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease26 October 2021 | International Journal of Molecular Sciences, Vol. 22, No. 21Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog29 October 2021 | Frontiers in Immunology, Vol. 12Deep Parallel Characterization of AAV Tropism and AAV-Mediated Transcriptional Changes via Single-Cell RNA Sequencing21 October 2021 | Frontiers in Immunology, Vol. 12Advances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy Grace Elizabeth Mulia, Virginia Picanço-Castro, Eleana F. Stavrou, Aglaia Athanassiadou, and Marxa Leão Figueiredo18 October 2021 | Human Gene Therapy, Vol. 32, No. 19-20Consequences of Mammalian Target of Rapamycin Inhibition on Adeno-Associated Virus Hepatic Transduction Efficacy Andrea Pérez-Iturralde, Beatriz Carte, and Rafael Aldabe18 October 2021 | Human Gene Therapy, Vol. 32, No. 19-20Brd4 Inactivation Increases Adenoviral Delivery of BMP2 for Paracrine Stimulation of Osteogenic Differentiation as a Gene Therapeutic Concept to Enhance Bone Healing23 June 2021 | JBMR Plus, Vol. 5, No. 10Envisioning treating genetically-defined urinary tract malformations with viral vector-mediated gene therapyJournal of Pediatric Urology, Vol. 17, No. 5X-linked myotubular myopathyNeuromuscular Disorders, Vol. 31, No. 10Genetic therapy for congenital myopathies13 July 2021 | Current Opinion in Neurology, Vol. 34, No. 5Polymeric Delivery of Therapeutic Nucleic Acids3 May 2021 | Chemical Reviews, Vol. 121, No. 18Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues7 July 2021 | Blood, Vol. 138, No. 11Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art25 August 2021 | International Journal of Molecular Sciences, Vol. 22, No. 17Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors3 August 2021 | International Journal of Molecular Sciences, Vol. 22, No. 15Emerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies22 June 2021 | Frontiers in Cellular Neuroscience, Vol. 15Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy30 December 2020 | Expert Opinion on Biological Therapy, Vol. 21, No. 6Juggling Safety and Efficacy: Finding Ways to Achieve Both Dan Wang16 June 2021 | Human Gene Therapy, Vol. 32, No. 11-12Human MiniPromoters for ocular-rAAV expression in ON bipolar, cone, corneal, endothelial, Müller glial, and PAX6 cells2 February 2021 | Gene Therapy, Vol. 28, No. 6Evolving AAV-delivered therapeutics towards ultimate cures16 February 2021 | Journal of Molecular Medicine, Vol. 99, No. 5Spinal Muscular AtrophySeminars in Pediatric Neurology, Vol. 37VectorMOD: Method for Bottom-Up Proteomic Characterization of rAAV Capsid Post-Translational Modifications and Vector Impurities1 April 2021 | Frontiers in Immunology, Vol. 12Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development20 April 2021 | Biomolecules, Vol. 11, No. 4Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions17 March 2021 | Frontiers in Immunology, Vol. 12Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre ExperienceJournal of Neuromuscular Diseases, Vol. 8, No. 2CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing Ishani Dasgupta, Terence R. Flotte, and Allison M. Keeler17 March 2021 | Human Gene Therapy, Vol. 32, No. 5-6Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatmentMolecular Therapy - Methods & Clinical Development, Vol. 20Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) modelsAdvanced Drug Delivery Reviews, Vol. 170Gene-based therapies for neurodegenerative diseases1 February 2021 | Nature Neuroscience, Vol. 24, No. 3Safe and low-dose but therapeutically effective adenovirus-mediated hepatocyte growth factor gene therapy for type 1 diabetes in miceLife Sciences, Vol. 268Engineering adeno-associated viral vectors to evade innate immune and inflammatory responsesScience Translational Medicine, Vol. 13, No. 580Overcoming innate immune barriers that impede AAV gene therapy vectors4 January 2021 | Journal of Clinical Investigation, Vol. 131, No. 1Quality Control Testing, Characterization and Critical Quality Attributes of Adeno‐Associated Virus Vectors Used for Human Gene Therapy27 November 2020 | Biotechnology Journal, Vol. 16, No. 1Arzneimittel für neuartige Therapien – Perspektiven, Chancen, Herausforderungen18 November 2020 | Monatsschrift Kinderheilkunde, Vol. 169, No. S1Respiratory care in myotubular myopathy21 January 2021 | ERJ Open Research, Vol. 7, No. 1Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back28 November 2020 | Journal of Personalized Medicine, Vol. 10, No. 4Therapeutic Angiogenesis by a “Dynamic Duo”: Simultaneous Expression of HGF and VEGF165 by Novel Bicistronic Plasmid Restores Blood Flow in Ischemic Skeletal Muscle18 December 2020 | Pharmaceutics, Vol. 12, No. 12New Therapeutics Options for Pediatric Neuromuscular Disorders23 November 2020 | Frontiers in Pediatrics, Vol. 8Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances11 November 2020 | Frontiers in Neuroscience, Vol. 14When the Capsid Meets the Promoter: A New Insight into Transgene Expression from Adeno-Associated Virus Vectors Arun Srivastava13 November 2020 | Human Gene Therapy, Vol. 31, No. 21-22Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methodsBiomaterials, Vol. 258Gene Therapy: It Is Time to Talk about High-Dose AAV The deaths of two children with X-linked myotubular myopathy in the ASPIRO trial prompts a reexamination of vector safety Nicole Paulk3 September 2020 | Genetic Engineering & Biotechnology News, Vol. 40, No. 9High-Resolution Histological Landscape of AAV DNA Distribution in Cellular Compartments and Tissues following Local and Systemic InjectionMolecular Therapy - Methods & Clinical Development, Vol. 18Laying the Foundation for Neuromuscular Disease Gene Therapy Dongsheng Duan17 August 2020 | Human Gene Therapy, Vol. 31, No. 15-16 Volume 31Issue 13-14Jul 2020 InformationCopyright 2020, by Mary Ann Liebert, Inc., publishersTo cite this article:James M. Wilson and Terence R. Flotte.Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy.Human Gene Therapy.Jul 2020.695-696.http://doi.org/10.1089/hum.2020.182Published in Volume: 31 Issue 13-14: July 15, 2020Online Ahead of Print:July 1, 2020Online Ahead of Editing: June 30, 2020PDF download